PF: Complication of Pancreatic Fistula and Bleeding After Pancreaticoduodenectomy in Treatment Periampullary Cancer

Sponsor
Vo Truong Quoc (Other)
Overall Status
Recruiting
CT.gov ID
NCT04985071
Collaborator
(none)
150
1
24.4
6.1

Study Details

Study Description

Brief Summary

This multi-site study will be done across Hepatobiliary and Pancreatic Surgery Department at Cho Ray Hospital and University and Pharmacy Center. Patients who are diagnosed with periampullary cancer from August 2021 to August 2023 will be underwent pancreaticoduodenectomy. We will follow-up for their pancreatic fistula and bleeding complication and analysis some risk factors.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Pancreaticoduodenectomy

Detailed Description

The investigator will conduct this study at both site at the same time: Cho Ray Hospital and University and Pharmacy Center. The investigator will directly consult the patient to participate in the study, collect the preoperative information, intraoperative protocol and postoperative data. The investigator will statically analysis the incident of the morbidity (mainly for pancreatic fistula and bleeding), and invest some risk factors relating to those complications.

Plan for conducting the study:
  • The patient diagnosed with periampullary cancer will be consulted with surgical method, operative risks, postoperative complications and agree to participate in the study. The patient signes a consent form to participate in the study.

  • Pancreaticoduodenectomy will be performed according to the uniformity protocol of both hospitals: Cho Ray Hospital and University of Medicine and Pharmacy Center.

  • Post-operative data will be collected and based on the general procedure.

Data analysis

  • To determine the incidence of pancreatic fistula and bleeding, survival analysis will be used.

  • To determine the association of risk factors with pancreatic fistula and bleeding, logistic regression was used, the value with p < 0.2 will be included in the multivariable regression model to determine the real risk factors.

Sample size:

• The investigator expect approximately 100 patients in the first year in both centers. And the investigator hope at least 150 patients in the whole conducting time.

Plan for missing data:

• The investigator will directly collect the patient information before the operation, observe the operation process and follow-up the postoperative during. Investigator will remove any case that missing preoperative information, operative data or post-operative laboratory test.

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
150 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Study of Pancreatic Fistula and Bleeding Complication After Pancreaticoduodenectomy in Treatment Periampullary Cancer
Actual Study Start Date :
Aug 18, 2021
Anticipated Primary Completion Date :
Jul 1, 2023
Anticipated Study Completion Date :
Aug 31, 2023

Outcome Measures

Primary Outcome Measures

  1. Pancreatic fistula [90 post-operative days]

    Rate of post-operative pancreatic fistula, risk factors associate to pancreatic fistula

Secondary Outcome Measures

  1. Bleeding complication [90 post-operative days]

    Rate and location of post-operative bleeding, risk factors relate to this complication

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Patients diagnosed with periampullary cancer meet the following criteria:

  • Possibility to perform pancreaticoduodenectomy based on preoperative imaging and intraoperative exploration.

  • The postoperative pathology is adenocarcinoma (of the ampulla of Vater, common bile duct, duodenum or pancreas)

Exclusion Criteria:
  • The patient has other organ's cancer beyond periampullary cancer.

  • Patient's medical conditions contraindicate for anesthesia.

  • The patient does not consent to participate in the study

Contacts and Locations

Locations

Site City State Country Postal Code
1 Phan Minh Tri Ho Chi Minh City Vietnam 700000

Sponsors and Collaborators

  • Vo Truong Quoc

Investigators

  • Principal Investigator: TruongQuoc Vo, Doctor, University of Medicine and Pharmacy at HoChiMinh City

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Vo Truong Quoc, General Surgery Department, Principal Investigator, Clinical Professor, University of Medicine and Pharmacy at Ho Chi Minh City
ClinicalTrials.gov Identifier:
NCT04985071
Other Study ID Numbers:
  • VTrQuoc
First Posted:
Aug 2, 2021
Last Update Posted:
Mar 9, 2022
Last Verified:
Feb 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Vo Truong Quoc, General Surgery Department, Principal Investigator, Clinical Professor, University of Medicine and Pharmacy at Ho Chi Minh City
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 9, 2022